• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

    351.00 -0.48 (-0.14%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about BeOne Medicines Ltd. - American Depositary Shares

    < Previous 1 2 3 4 5 Next >
    News headline image
    BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
    From BeOne Medicines, Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript ↗
    BRUKINSA revenue surged 31% while management raised full-year guidance by $300 million. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Q2 Earnings Call Highlights ↗
    BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued... 
    Via MarketBeat
    Topics Earnings
    News headline image
    BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position ↗
    Executed under pre-established trading plan, this sale reduces the chief executive's direct holdings by just 2%. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 ↗
    BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company... 
    Via MarketBeat
    News headline image
    BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
    This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials. 
    Via The Motley Fool
    News headline image
    What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
    Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
    Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach. 
    Via The Motley Fool
    Topics Initial Public Offering
    News headline image
    Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
    This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
    From BeOne Medicines Ltd
    Via Business Wire
    News headline image
    U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
    From BeOne Medicines Ltd.
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.